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Abstract
In children with Sickle Cell Disease, the combination of risk stratification with Transcranial 
Doppler Ultrasound (TCD) and selective chronic red cell transfusion (CRCT—the STOP Protocol) 
is one of the most effective stroke prevention strategies in medicine. How fully it is being 
implemented is unclear.
Nineteen of 26 sites that conducted the two pivotal clinical trials (STOP and STOP II) participated 
in Post STOP, a comprehensive medical records review assessing protocol implementation in the 
10-15 years since the trials ended. Professional abstractors identified medical records in the Post 
STOP era in 2851 74% of the 3840 children who took part in STOP and/or STOP II, and 
documented TCD rescreening, maintenance of CRCT in those at risk, and stroke.
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Among 1896 children eligible for TCD rescreening (target group), evidence of any rescreening 
was found in 1090 (57%). There was wide site variation in TCD rescreening ranging from 18% to 
91% of eligible children. Both younger age and having a conditional TCD during STOP/II were 
associated with a higher likelihood of having a TCD in Post STOP. Sixty eight new abnormal, high 
risk cases were identified.
Despite clear evidence of benefit the STOP protocol is not fully implemented even at experienced 
sites. Site variation suggests that system improvements might remove barriers to implementation 
and result in even greater reduction of ischemic stroke in children with SCD.
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INTRODUCTION
The primary prevention of ischemic stroke in children with Sickle Cell Disease was made 
possible by stroke risk stratification using transcranial Doppler ultrasound (TCD) (1). When 
high risk cases identified by TCD received chronic red cell transfusion (CRCT) in a 
randomized, controlled, multicenter clinical trial (Stroke Prevention in Sickle Cell Anemia
—the STOP Study) there was a marked reduction (> 90%) in first stroke compared to 
standard care(2). A second trial, Optimizing Stroke Prevention in Sickle Cell Disease- STOP 
II) failed to show that transfusion could be withdrawn safely even after 30 or more months 
of CRCT (3). Between 1995 and 2005, STOP and STOP II, were performed in the US and 
Canada and involved 26 centers specializing in the care of children with sickle cell disease 
(2)(3). The centers identified children with Hemoglobin SS or Sbeta0thal who were then 
consented to have TCD. The role of TCD, methods of performance, interpretation, and the 
design of the studies have been described elsewhere (4). TCD stratifies stroke risk on the 
basis of blood flow velocity in the internal carotid or middle cerebral arteries. Categories 
derived from a large single center prospective study (1) were used: Time averaged mean of 
the maximum (TAMM) < 170 cm/sec normal; 170-199 cm/sec conditional and 200 cm/sec 
or greater for abnormal eligible for randomization in the treatment (CRCT vs standard care) 
part of the trial. Criteria for STOP II (randomized withdrawal of CRCT) were that the 
subject had to have had a high risk TCD followed by at least 30 months of CRCT and have a 
low risk TCD at randomization. Participation in these studies ranged from a single screening 
TCD to randomization. STOP II also had an observational arm for children on CRCT whose 
TCD had not reverted to normal.
This protocol, known as the STOP Protocol, became widely recommended in 1998 and since 
then reduction in stroke in children with Sickle Cell Disease (SCD) has been reported in 
clinic series (5)(6)(7), and from hospitalization data when time frames after 1998 are 
compared to years prior to 1998 (8)(9)(10)(11). In addition, a marked reduction in the black-
white childhood disparity in the risk of dying from ischemic stroke (from 1.74 to 1.27 
Relative Risk blacks more likely than whites) has been attributed to the widespread 
implementation of the STOP Protocol (12). These data suggest that substantial 
implementation of the stroke prevention protocol has taken place and stroke reduction has 
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been realized, but it is not clear to what extent the benefits of this research have extended to 
all children at risk.
Problems with access to, or compliance with, TCD screening remain important barriers to 
full dissemination and implementation of the STOP protocol (13)(14). Guidelines called for 
yearly TCD from age 2-16 years if the results remained in the normal range. More frequent 
TCD's should be performed if conditional results were observed, especially in younger 
children with velocities closer to 200 cm/sec (15)(16). Adherence to the guidelines varies 
widely, from 45% (2004-2006) to 68% (2008) (17) but substantial numbers of children 
(31%) received few if any TCD examinations over 10 years after publication of the STOP 
study (18). While Medicaid claims data analysis showed an increase from 22% to 44% from 
2005-2010 there was substantial variation across states and overall screening rates remain 
low (19).
The participation of almost 4000 children with SCD in either or both the STOP or STOP II 
studies represents a unique opportunity to examine real world stroke prevention practices 
after the clinical trials ended in centers that conducted the studies. This is the initial report 
from the Post STOP Study, an NIH funded project which sought to re-identify and locate (in 
the medical record) as many of the participants of STOP and/or STOP II as possible to 
compare: 1) actual TCD screening patterns/practices after the trials ended and 2) initiation 
and maintenance of CRCT when high risk was discovered, to the STOP protocol guidelines 
(idealized implementation). A third aim was to categorize the Post STOP ischemic strokes as 
either presumed failures of risk detection (with TCD) or failures of risk mitigation (with 
CRCT). This paper reports TCD rescreening in those younger subjects eligible for TCD by 
protocol.
These data will inform efforts to further reduce stroke and advance the NHLBI goal of a 
“stroke free generation” in Sickle Cell Disease (20) by identifying gaps in implementation or 
protocol efficacy leading to targeted intervention strategies.
METHODS
For all participants of STOP/II a date was identified at which they had their last encounter/
data entry in these studies. The period of study for Post STOP was individually determined 
and extended from this date to the date when records of care were abstracted at the study 
sites. No effort was made to locate records of care from outside centers.
Definition of Idealized STOP TCD Screening Implementation:
1) Children age 2-16 years get yearly TCD unless:
a. Conditional TCD is detected, which should prompt more 
frequent TCD (not otherwise specified except that frequency 
should be based on age—younger children and those with TCD 
velocities closer to 200 cm/sec getting more TCD).
b. If abnormal TCD is detected, either CRCT should be initiated 
or early repeat (within 4 weeks) TCD should be performed and 
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if abnormal CRCT initiated or if conditional TCD should be 
repeated. Initially the STOP Protocol called for repeating an 
Abnormal TCD within 4 weeks to confirm high risk prior to 
starting transfusion. However, in both STOP and STOP II 
strokes were documented in the period between tests leading to 
recommendations for transfusion after a single abnormal. 
Because of this variance either transfusion or early repeat of 
TCD are considered consistent with idealized implementation.
2) Inadequate TCD, caused by either technical problems or severe arterial disease 
with occlusion of the arteries of interest, provides no clear indication of risk. 
While repeat TCD or alternate methods of evaluation such as magnetic 
resonance angiography are often performed guidelines in the Post STOP era do 
not provide specific recommendations.
Chart Abstraction
Institutional Review Board approval was obtained from participating sites. Subjects who 
participated in STOP or STOP II were identified from their study acrostic. A data abstraction 
team visited each site and examined all available inpatient and outpatient records for that 
site's subjects from the Post STOP date up to the visit date or far as possible for those no 
longer being cared for at that site. Abstraction visits began in January 2012 and ended in 
May 2014. All TCD data, any brain neuroimaging test results, and all available written 
materials pertaining to any neurological events were de-identified and retrieved for later 
analysis.
Post STOP TCD results were classified from written reports into STOP Protocol categories: 
Normal (< 170 cm/sec Time averaged Mean of the Maximum); Conditional (170-199 cm/
sec); Abnormal (≥ 200 cm/sec) or Inadequate. Cases where the report included velocities 
were interpreted and classified by the investigative team according to STOP criteria 
regardless of the local reading.
Statistical Methods
Descriptive statistics were performed using chi-square and t-tests for categorical and 
continuous data, respectively. Last STOP/ II visit was considered to be the start of Post 
STOP study. As such, age at start of Post STOP was calculated as age at last STOP/II visit. 
Follow-up time subsequently calculated as the time from last STOP/II visit to last encounter 
in medical charts during Post STOP era.
RESULTS
The two study data (STOP and STOP II) bases contained unique records on 3854 children at 
26 sites. Nineteen of these sites participated in Post STOP but these sites accounted for 3539 
subjects (92%). Of these 3539, records of care at the enrolling sites in the Post STOP era 
were located 2851 (81% of possible at participating sites) (Figure 1). The mean age of 
subjects at the start of their individual Post STOP period was 10.5+4.6 (median 10.4 (range 
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2.0-23.2)). The mean follow-up time from last STOP/II visit was 9.1+3.4 years (median 10.3 
(range <1 year-15.4 years)).
TCD Rescreening
Subjects with conditions or age that precluded TCD rescreening by the protocol were 
excluded from the following analysis. This included any subject with abnormal TCD or 
stroke during the STOP/II era and those falling outside age guidelines. Removing subjects 
entering Post STOP with abnormal TCD (n=333), those whose last TCD was inadequate 
(n=135), those with stroke (n=41) and subjects within 12 months of their 17th birthday 
(n=441) reduced the rescreening candidates from 2851 to 1896 (Figure 1). Among these 
1896, 49% were female and the mean age was 8.7+3.5 at the start of Post STOP. The last 
TCD in STOP/II was conditional for 208 (11%) and normal for 1688 (89%). Evidence of at 
least one Post STOP TCD was found in 1090 (57%). The number of TCD's per subject 
varied widely (Figure 2). Age (p<0.0001) but not gender (p=0.33) was associated with being 
rescreened. The percentage of subjects who had TCD rescreening varied by site, ranging 
from 18% to 91% (Figure 3). To determine if low overall screening rates reflected a bias at 
some sites to screen only younger children, the rates were determined deleting children who 
were or would turn 11 years of age or older one year into Post STOP. Rescreening rates 
ranged from 27% to 98% but the relative performance changed little. The four lowest 
performing sites and three of the 4 top performing sites were the same in both analyses.
Having a conditional TCD during STOP/II increased the likelihood of having TCD in Post 
STOP but only if the last TCD was conditional. For those with any conditional during the 
two trials 60% had TCD (vs 57% overall, p=.18). However, if the last TCD in STOP/II was 
conditional 69% had TCD in Post STOP (compare to 56% overall, p=.0003). Among those 
eligible for rescreening, 68 converted to abnormal TCD (37 from Normal and 31 from 
Conditional-- last TCD in STOP/II) at a mean age of 9.0+3.3 (range 4.0 to 19.6 years). 
(Figure 1).
DISCUSSION
Post STOP documented considerable variation in implementation of the STOP TCD 
Screening Protocol with 5 sites achieving > 80% of eligible children having at least one 
TCD while 4 sites achieved < 27%. Since these were experienced sites it is likely that results 
generally may be worse. The results were changed little by looking only at younger children 
suggesting that some sites have developed very effective ways to carry out TCD rescreening 
while others have not. No evidence could be found for TCD rescreening in 43% of those 
eligible. Since these sites all had TCD screening programs, this represents difficulties in 
implementation rather than dissemination. The advantages of Post STOP are that extended 
follow up was obtained on a large cohort who had standardized stroke risk assessments as 
part of a clinical trial that established a baseline for stroke risk. The medical care examined 
was from centers that participated in the trials and where it is presumed that protocol 
implementation would be optimal compared to the medical community at large. Trained 
abstractors visited each site and used consistent survey tools and procedures. Important 
limitations: 1) chart review can generally only produce positive evidence of, rather than 
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confirm absence of, testing or treatment; 2) Abstractors encountered both paper and 
electronic records and charts may have been missing important data or abstractors may have 
missed important information on screening, transfusion decisions and compliance; 3) only 
about half of the participating centers had integrated pediatric and adult medical records 
which meant that important information on treatment after transfer to the adult system was 
missing on subjects at some sites; 4) it is possible but unlikely that substantially different 
outcomes might have taken place in the 984 children who could not be located.
Regarding these limitations
1) it is unlikely that many children underwent TCD screening outside of these centers unless 
they relocated to other cities with comprehensive SCD centers as access was limited during 
this period making it unlikely that institutions in the area of participating sites offered 
competitive services; 2) chart abstraction is imperfect but the team experienced in the 
exercise for 3 years would be unlikely to miss substantial data when using the same 
examination template; 3) the lack of visibility into the adult treatment limits conclusions 
regarding problems during care transition but it does not affect the positive findings of the 
study because TCD protocol implementation was examined only in children; 4) protocol 
adherence was probably worse rather than better in those not located unless they transferred 
care to another SCD Comprehensive Center.
Also during this period use of hydroxyurea increased, but was not likely to have influenced 
the rescreening rate. Recently the results of the TWiTCH study were published. In this study 
children with abnormal TCD (but without severe vasculopathy on magnetic resonance 
angiograpy) were randomized to either continue transfusion after one year or be transitioned 
to hydroxyurea. No change in TCD was reported after two years on HU and no strokes 
occurred in the subjects removed from transfusion (21). Their results may spur TCD 
screening with renewed interest as long-term transfusion may not be needed in all children 
identified as high risk provided they are identified early before severe vasculopathy becomes 
established.
While the use of TCD for risk stratification in SCD is not controversial, guidelines 
acknowledge that the optimal timing and frequency of screening are not evidence based. 
There is not universal acceptance of the need for yearly TCD in older children and some 
have advocated not screening older children who have had normal TCD in early childhood. 
In the French newborn cohort study no first time abnormals were noted over the age of nine 
years (7). However, both STOP (22) and Post STOP documented a low but non-zero 
abnormal “find rate” in older children. The French study is not typical in that intensive 
efforts were made for regular TCD and follow up from an early age, unlike clinical 
experience outside a research cohort. However, it does suggest that with early and repeat 
TCD, evidence could indicate that at some point screening beyond a certain age is not 
necessary. Until such data are available recommendations remain in place for screening from 
ages 2 -16 years. Nonetheless Post STOP and the Medicaid Claims data (19) both show that 
older children were less likely to obtain TCD rescreening. However, the marked variation in 
site performance in Post STOP was not explained by age selectivity at these sites. The care 
of children with SCD is challenging. These results suggest that institutional programs (such 
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as computerized monitoring of regular TCD screening with outreach to those who miss 
appointments) may have a substantial impact on STOP TCD Protocol implementation.
Conclusions
Even at experienced sites TCD screening to detect risk for primary stroke is rarely 
implemented according to protocol. Special programs aimed at improving implementation of 
TCD screening would be likely to further reduce ischemic stroke in Sickle Cell Disease.
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Subject status in Post STOP
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Number of TCD's in Post STOP
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Percent of subjects with at least 1 TCD during Post STOP by Clinical Site
Adams et al. Page 11
Am J Hematol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
